Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Care Oncology Clinic offers a supervised treatment regimen for people diagnosed with cancer of any type or stage. AVRT is a physician-led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Its program includes a comprehensive online health evaluation; bloodtests to measure markers of inflammation and metabolism; an initial physician consultation; regular physician follow-up appointments and interval screening. Its additional cancer diagnostics include ColonSentry and the Prostate Health Index.


TSX:SZLS - Post by User

Comment by RelevantStockon Aug 09, 2020 6:12pm
126 Views
Post# 31385102

RE:RE:RE:RE:RE:RE:RE:RE:RE:The next week will be monumental.

RE:RE:RE:RE:RE:RE:RE:RE:RE:The next week will be monumental.
SAGDollar wrote: I think Mercer will be a teriffic partner to market Aristotle


Ah yeah definitely the best. Aristotle will benefit the most to the employers that offer insurance plans to a large pool of workers, allowig them to save huge costs on cancer treatments (in USA). I am here mostly for covid revenue for the moment though, as much as I like Aristotle and believe in its future. Glad they are working on following the prospectus plan, I have them in high respect for helping fight the pandemic, but I'll need to better see a big lighthouse to stay onboard after the Q3 hype. I was 100% believer but would have liked a follow up PR or two, after a (first) very abrupt ER for q4 q1.
<< Previous
Bullboard Posts
Next >>